Literature DB >> 35342870

Demonstrating an Analyses of Clinical Data Evaluating Psychotropic Medication Reductions and the ACHIEVE! Program in Adolescents with Severe Problem Behavior.

Alison D Cox1, Duncan Pritchard2, Heather Penney2, Llio Eiri2, Tim J Dyer2.   

Abstract

Researchers report increasing trends in psychotropic medication use to treat problem behavior in individuals with intellectual and developmental disability, despite some controversy regarding its application and treatment efficacy. A substantial evidence base exists supporting behavioral intervention efficacy, however research evaluating separate and combined intervention (i.e., concurrent application of behavioral and psychopharmacological interventions) effects remains scarce. This article demonstrates how a series of analyses on clinical data collected during treatment (i.e., four case studies) may be used to retrospectively explore separate and combined intervention effects on severe problem behavior. First, we calculated individual effect sizes and corresponding confidence intervals. The results indicated larger problem behavior decreases may have coincided more often with behavioral intervention adjustments compared to medication adjustments. Second, a conditional rates analysis indicated surges in problem behavior did not reliably coincide with medication reductions. Spearman correlation analyses indicated a negative relationship between behavioral intervention phase progress and weekly episodes of problem behavior compared to a positive relationship between total medication dosage and weekly episodes of problem behavior. However, a nonparametric partial correlation analyses indicated individualized, complex relationships may exist among total medication dosage, behavioral intervention, and weekly episodes of problem behavior. We discuss potential clinical implications and encourage behavioral researchers and practitioners to consider applying creative analytic strategies to evaluate separate and combined intervention effects on problem behavior to further explore this extremely understudied topic. Supplementary Information: The online version contains supplementary material available at 10.1007/s40614-020-00279-3. © Association for Behavior Analysis International 2021.

Entities:  

Keywords:  Adolescents with intellectual and developmental disability; Polypharmacy; Psychopharmacological interventions; Severe problem behavior; The ACHIEVE! program

Year:  2021        PMID: 35342870      PMCID: PMC8894527          DOI: 10.1007/s40614-020-00279-3

Source DB:  PubMed          Journal:  Perspect Behav Sci        ISSN: 2520-8969


  35 in total

Review 1.  Interactions between behavior function and psychotropic medication.

Authors:  Alison D Cox; Javier Virues-Ortega
Journal:  J Appl Behav Anal       Date:  2015-09-22

2.  Social validity: the case for subjective measurement or how applied behavior analysis is finding its heart.

Authors:  M M Wolf
Journal:  J Appl Behav Anal       Date:  1978

3.  Some determinants of changes in preference over time.

Authors:  Gregory P Hanley; Brian A Iwata; Eileen M Roscoe
Journal:  J Appl Behav Anal       Date:  2006

4.  How to select, calculate, and interpret effect sizes.

Authors:  Joseph A Durlak
Journal:  J Pediatr Psychol       Date:  2009-02-16

5.  Board Certified Behavior Analysts and Psychotropic Medications: Slipshod Training, Inconsistent Involvement, and Reason for Hope.

Authors:  Anita Li; Alan Poling
Journal:  Behav Anal Pract       Date:  2018-02-23

6.  Confidence interval or p-value?: part 4 of a series on evaluation of scientific publications.

Authors:  Jean-Baptist du Prel; Gerhard Hommel; Bernd Röhrig; Maria Blettner
Journal:  Dtsch Arztebl Int       Date:  2009-05-08       Impact factor: 5.594

7.  Effect Size for Single-Subject Design in Phonological Treatment.

Authors:  Judith A Gierut; Michele L Morrisette; Stephanie L Dickinson
Journal:  J Speech Lang Hear Res       Date:  2015-10       Impact factor: 2.297

8.  Physicians' reasons not to discontinue long-term used off-label antipsychotic drugs in people with intellectual disability.

Authors:  G M de Kuijper; P J Hoekstra
Journal:  J Intellect Disabil Res       Date:  2017-05-30

9.  Assessing the Impact of Psychotropic Medication Changes on Challenging Behavior of Individuals with Intellectual Disabilities.

Authors:  Maria G Valdovinos; Meara Henninger-McMahon; Elizabeth Schieber; Lisa Beard; Brenna Conley; Annette Haas
Journal:  Int J Dev Disabil       Date:  2016-04-28

10.  Antipsychotic Use With and Without Comorbid Psychiatric Diagnosis Among Adults with Intellectual and Developmental Disabilities.

Authors:  Yona Lunsky; Wayne Khuu; Mina Tadrous; Simone Vigod; Virginie Cobigo; Tara Gomes
Journal:  Can J Psychiatry       Date:  2017-08-22       Impact factor: 4.356

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.